Soligenix Hits Key Enrollment Milestone in Phase 3 Trial for HyBryte™ in Cutaneous T-Cell Lymphoma
Soligenix, Inc. (Nasdaq: SNGX), a late-stage biopharmaceutical company dedicated to developing and commercializing therapies for rare diseases with high unmet needs, announced the completion of the targeted enrollment of 50 patients required for the planned interim analysis in its 80-patient confirmatory Phase
